anti-PIAS1 (PIAS1) Antikörper

Mouse (Murine) Protein Inhibitor of Activated STAT, 1 (PIAS1) Interaktionspartner

1. these results indicate that PIAS1 is a positive regulator of MYC (zeige MYC Antikörper).

2. PIAS1 overexpression exacerbated mutant Huntingtin-associated (zeige KALRN Antikörper) phenotypes and aberrant protein accumulation

3. Pias1 expression in primary myoblasts enhances the induction of cardiac muscle genes MyoD (zeige MYOD1 Antikörper), Myogenin (zeige MYOG Antikörper) and Myomaker. Endothelial cell specific inactivation of Pias1 in vivo impairs yolk sac (zeige ADCY10 Antikörper) erythrogenesis, angiogenesis and recapitulates loss of myocardium muscle mass. Pias1 is an essential gene for YS erythropoiesis and vasculogenesis in vivo.

4. Data suggest overexpression of Pias1 in white adipose tissue (WAT) of obesity/prediabetes improves insulin (zeige INS Antikörper) resistance; knockdown of Pias1 in normal WAT leads to insulin (zeige INS Antikörper) resistance; Pias1 expression in WAT is down-regulated by c-Jun N-terminal kinase.

5. Between the E3 SUMO ligase PIAS1 and STAT-3 (zeige STAT3 Antikörper).

6. Knockdown of PIAS1 in astrocytes impairs the accumulation of nuclear STI1 (zeige STIP1 Antikörper) in response to irradiation. Moreover, a PIAS1 mutant lacking the STI1 (zeige STIP1 Antikörper) binding site is unable to increase STI1 (zeige STIP1 Antikörper) nuclear retention.

7. A novel role of PIAS1 in maintaining the quiescence of dormant hematopoietic stem cells and in the epigenetic repression of the myeloerythroid program.

8. The present study showed that PIAS1 functions as a SUMO E3 ligase of C/EBPbeta (zeige CEBPB Antikörper) to regulate adipogenesis.

9. Piasy (zeige PIAS4 Antikörper) represses the synergistic activation of PITX2 (zeige PITX2 Antikörper) with interacting co-factors and Piasy (zeige PIAS4 Antikörper) represses Pias1 activation of PITX2 (zeige PITX2 Antikörper) transcriptional activity.

10. MAPK-activated protein kinase-2 limits endothelial inflammation via the PIAS1 S522 phosphorylation-mediated increase in PIAS1 transrepression and SUMO ligase activity.

Human Protein Inhibitor of Activated STAT, 1 (PIAS1) Interaktionspartner

1. these results indicate that PIAS1 is a positive regulator of MYC (zeige MYC Antikörper).

2. PIAS1 is a prognostic biomarker in breast cancer

3. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer

4. PIAS1 overexpression exacerbated mutant Huntingtin-associated (zeige KALRN Antikörper) phenotypes and aberrant protein accumulation

5. HBs protein-induced hPIAS1 transcription requires TAL1 (zeige TAL1 Antikörper), E47 (zeige TCF3 Antikörper), MYOG (zeige MYOG Antikörper), NFI (zeige NFIC Antikörper), and MAPK (zeige MAPK1 Antikörper) signal pathways

6. identified the SUMO ligase PIAS1 as a constituent PML (zeige PML Antikörper)-NB antiviral protein. This finding distinguishes a SUMO ligase that may mediate signaling events important in promyelocytic leukemia (zeige PML Antikörper) nuclear body mediated intrinsic immunity.

7. PIAS1 enhances p300 (zeige EP300 Antikörper) recruitment to c-Myb (zeige MYB Antikörper)-bound sites through interaction with both proteins. In addition, the E3 activity of PIAS1 enhances further its coactivation

8. Results show that apocrine breast cancer and prostate cancer cells share a core AR cistrome and target gene signature linked to cancer cell growth, and PIAS1 plays a similar coregulatory role for AR in both cancer cell types.

9. c-Myc (zeige MYC Antikörper) is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 (zeige SENP7 Antikörper) and RNF4 (zeige RNF4 Antikörper)

10. Data demonstrate that PIAS1 interacts with TRF2 (zeige TERF2 Antikörper) and mediates its sumoylation serving as a molecular switch that controls the level of TRF2 (zeige TERF2 Antikörper) at telomeres.